Therapy-Related Myeloid Neoplasms in Patients with Neuroendocrine Neoplasms after Peptide Receptor Radionuclide Therapy: A Systematic Review


Introduction: Therapy-related myeloid neoplasm (t-MN) has been reported as a potential long-term and frequently lethal adverse event after PRRT in NET. However, the incidence, time of diagnosis, and nature of t-MN is unclear.

Aim(s): In this systematic review, we aimed to evaluate the literature and report the incidence, time of diagnosis, and nature of t-MN after PRRT

Materials and methods: We searched different databases for articles reporting studies of different designs evaluating>1 patient (RCTs, prospective phase I or phase II, retrospective studies, and case series). Studies of interest included patients with NET who were treated with PRRT and reported the incidence of t-MN. The primary outcome was the incidence of t-MN

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sonbol M

Authors: Sonbol M, Hilal T, Halfdanarson T,

Keywords: PRRT, t-MN, therapy-related myeloid neoplasm, leukemia, NET, MDS,

To read the full abstract, please log into your ENETS Member account.